Status:
COMPLETED
18F-FSPG PET/CT in Diagnosing Early Lung Cancer in Patients With Lung Nodules
Lead Sponsor:
Andrei Iagaru
Collaborating Sponsors:
Canary Foundation
Boston University
Conditions:
Cigarette Smoker
Current Smoker
Eligibility:
All Genders
45+ years
Phase:
PHASE2
Brief Summary
This phase II trial studies how well 18F-FSPG positron emission tomography (PET)/computed tomography (CT) work in diagnosing early lung cancer in patients with indeterminate lung nodules. PET imaging ...
Detailed Description
PRIMARY OBJECTIVES: I. Comparison of fluorine F 18 L-glutamate derivative BAY94-9392 (18F-FSPG) accumulation with fludeoxyglucose F-18 (18F-FDG) accumulation to assess whether (4S)-4-(3-18F-Fluoropro...
Eligibility Criteria
Inclusion
- Pulmonary nodule between the size of 7 to 30 mm. Subjects with multiple nodules may be eligible if the dominant nodule is 7 to 30 mm
- Undergoing standard of care 18F-FDG PET imaging (for indeterminate pulmonary nodule)
- Current or former cigarette smoker, with \>= 20 pack years
- Documented informed consent
Exclusion
- History or previous diagnosis of lung cancer
- Cancer diagnosis within the last 5 years
- Pregnant or nursing
Key Trial Info
Start Date :
February 4 2019
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
July 30 2021
Estimated Enrollment :
15 Patients enrolled
Trial Details
Trial ID
NCT03824535
Start Date
February 4 2019
End Date
July 30 2021
Last Update
April 9 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Stanford Cancer Institute Palo Alto
Palo Alto, California, United States, 94304